The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Prostate Specific Antigen (PSA) Test Market Increase Between 2026 And 2030?
The prostate specific antigen (psa) test market size has expanded considerably in recent years. Projections indicate it will increase from $4.65 billion in 2025 to $5.19 billion in 2026, at a compound annual growth rate (CAGR) of 11.7%. This historical expansion can be ascribed to several factors, including the increasing application of psa testing in clinical settings, the expansion of laboratory diagnostic services, a heightened awareness of prostate cancer screening, the widespread availability of immunoassay-based test kits, and the incorporation of psa testing into routine medical examinations.
The prostate specific antigen (psa) test market is projected for swift expansion in the upcoming years. This market is anticipated to reach a valuation of $8.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. Key factors contributing to this anticipated growth include the progress in high-precision PSA assay technologies, an increasing uptake of decentralized diagnostic testing, the broadening of preventive cancer screening initiatives, elevated investments in diagnostic automation, and a heightened demand for economical screening methods. Significant trends observed during this period are the wider integration of routine PSA screening programs, an escalating demand for point-of-care PSA testing, the increased utilization of high-sensitivity immunoassays, the expansion of post-treatment monitoring applications, and an intensified focus on identifying cancer at earlier stages.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12576&type=smp
Which Major Factors Are Contributing To The Development Of The Prostate Specific Antigen (PSA) Test Market?
The increasing prevalence of prostate cancer is anticipated to stimulate the expansion of the prostate-specific antigen (PSA) test market moving forward. Prostate cancer is defined as a condition where malignant cells originate in the prostate gland, which is a component of both male and female reproductive systems. The prostate-specific antigen (PSA) test is frequently employed as a screening method for prostate cancer in men. This test measures PSA levels in the bloodstream, thereby assisting in early detection and risk assessment. As an illustration, in March 2023, reports from the American Society of Clinical Oncology (ASCO), a US-based professional oncology organization, revealed that approximately 288,300 men in the US were diagnosed with prostate cancer, and roughly 34,700 people died in 2023. Hence, the escalating incidence of prostate cancer acts as a primary catalyst for the growth of the prostate-specific antigen (PSA) test market.
How Is The Prostate Specific Antigen (PSA) Test Market Examined Through Segment Analysis?
The prostate specific antigen (psa) test market covered in this report is segmented –
1) By Type: Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence Immunoassay (FIA), Other Types
2) By Application: Screening, Post-Treatment Monitoring, Other Applications
3) By End User: Hospitals, Diagnostic Centers, Research Institutes, Other End Users
Subsegments:
1) By Clinical Laboratory Improvement Amendments (CLIA): CLIA Waived Tests, Non-CLIA Tests
2) By Enzyme-Linked Immunosorbent Assay (ELISA): Sandwich ELISA Kits, Competitive ELISA Kits
3) By Fluorescence Immunoassay (FIA): Point-Of-Care FIA, Laboratory-Based FIA
4) By Other Types: Chemiluminescent Immunoassay (CLIA), Radioimmunoassay (RIA)
Which Trends Are Guiding The Development Of The Prostate Specific Antigen (PSA) Test Market?
Major companies operating in the prostate health market are strategically focusing on technological advancements, such as AI-powered risk assessment, to gain a competitive advantage. AI-powered risk assessment leverages artificial intelligence algorithms to analyze data and predict potential risks, thereby aiding in making informed decisions and improving outcomes. For instance, in September 2024, Nanostics Inc., a Canada-based clinical-stage biotechnology company, and Protean BioDiagnostics, a US-based biotechnology company, formed a partnership to introduce CDX Prostate, a diagnostic tool targeting men at risk of aggressive prostate cancer. This diagnostic tool incorporates biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer. CDX Prostate employs advanced machine learning algorithms to analyze diverse biological and clinical data, offering a more accurate risk score for aggressive prostate cancer than traditional methods. The test empowers healthcare providers and patients to make educated decisions about whether to proceed with a biopsy after a high prostate-specific antigen (PSA) test result or an abnormal digital rectal exam (DRE).
Who Are The Major Companies Operating In The Prostate Specific Antigen (PSA) Test Market?
Major companies operating in the prostate specific antigen (psa) test market are Siemens AG, F Hoffmann La Roche AG, Abbott Laboratories, Becton Dickinson And Company, PerkinElmer Inc, Beckman Coulter Inc, Bio Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, DiaSorin SpA, OPKO Health Inc, R And D Systems Inc, Meso Scale Diagnostics LLC, Tosoh America Inc, Fujirebio Europe NV, Boditech Med Inc, DRG International Inc, Enzo Life Sciences Inc, RayBiotech Inc, Novus Biologicals LLC, Creative Diagnostics Inc, Elabscience, LifeSpan BioSciences Inc, Accuquik Inc
Access The Complete Prostate Specific Antigen (PSA) Test Market Report:
Which Geographic Region Represents The Largest Prostate Specific Antigen (PSA) Test Market Share?
North America was the largest region in the prostate specific antigen (PSA) test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate specific antigen (psa) test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Prostate Specific Antigen (PSA) Test Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12576&type=smp
Browse Through More Reports Similar to the Global Prostate Specific Antigen (PSA) Test Market 2026, By The Business Research Company
Prostate Cancer Drugs Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2026
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model